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Background
The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that among 
high-risk patients with aortic stenosis, the 1-year survival rates are similar with trans-
catheter aortic-valve replacement (TAVR) and surgical replacement. However, longer-
term follow-up is necessary to determine whether TAVR has prolonged benefits.
Methods
At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis 
to undergo either surgical aortic-valve replacement or TAVR. All patients were fol-
lowed for at least 2 years, with assessment of clinical outcomes and echocardiographic 
evaluation.
Results
The rates of death from any cause were similar in the TAVR and surgery groups 
(hazard ratio with TAVR, 0.90; 95% confidence interval [CI], 0.71 to 1.15; P = 0.41) and 
at 2 years (Kaplan–Meier analysis) were 33.9% in the TAVR group and 35.0% in the 
surgery group (P = 0.78). The frequency of all strokes during follow-up did not differ 
significantly between the two groups (hazard ratio, 1.22; 95% CI, 0.67 to 2.23; 
P = 0.52). At 30 days, strokes were more frequent with TAVR than with surgical re-
placement (4.6% vs. 2.4%, P = 0.12); subsequently, there were 8 additional strokes in 
the TAVR group and 12 in the surgery group. Improvement in valve areas was similar 
with TAVR and surgical replacement and was maintained for 2 years. Paravalvular 
regurgitation was more frequent after TAVR (P<0.001), and even mild paravalvular 
regurgitation was associated with increased late mortality (P<0.001).
Conclusions
A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative 
to surgery in high-risk patients. The two treatments were similar with respect to 
mortality, reduction in symptoms, and improved valve hemodynamics, but paraval-
vular regurgitation was more frequent after TAVR and was associated with in-
creased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, 
NCT00530894.)
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Aortic stenosis is associated with high mortality after the appearance of car-diac symptoms.1 Nevertheless, many pa-
tients do not undergo surgical aortic-valve replace-
ment owing to real or perceived increased risks 
associated with surgery.2-5 Transcatheter aortic-
valve replacement (TAVR) has emerged as an al-
ternative therapy in high-risk patients with aortic 
stenosis.6-10 Observational registries from vari-
ous countries have reported 1-month and 1-year 
outcomes after TAVR,11-14 but there are limited 
long-term follow-up data.15
The Placement of Aortic Transcatheter Valves 
(PARTNER) trial was a randomized trial compar-
ing TAVR with standard-of-care therapies in high-
risk patients with aortic stenosis. One-year mor-
tality outcomes from PARTNER showed that TAVR 
was superior to standard therapy in patients who 
could not undergo surgery16 and was noninferior 
to surgical replacement in high-risk patients who 
could undergo surgery.17 However, longer-term 
data are required to assess valve durability and 
to monitor late clinical complications, before 
TAVR is used more widely in clinical practice. 
This report describes the 2-year (and longer) clini-
cal outcomes and echocardiographic findings after 
TAVR or surgical aortic-valve replacement in the 
high-risk patients in the PARTNER trial who could 
undergo surgery.
Me thods
Patients
Patient selection for this cohort of the PARTNER 
trial has been described previously.17 Inclusion cri-
teria were severe symptomatic aortic stenosis (an 
aortic-valve area ≤0.8 cm2 plus a peak velocity ≥4 m 
per second or a mean valve gradient ≥40 mm Hg) 
and high-risk status for surgical aortic-valve re-
placement, as determined by experienced surgeons. 
Patients were considered to be at high surgical 
risk if they had coexisting conditions that were 
associated with a risk of death of at least 15% by 
30 days after the operation.
Study Device and Procedure
The SAPIEN heart-valve system (Edwards Life-
sciences) and the TAVR procedure have been de-
scribed previously.16,17 Most procedures were per-
formed in a hybrid operating room with a fixed 
fluoroscopic imaging system, while the patient was 
under general anesthesia, and with transesopha-
geal echocardiography. Transapical TAVR was per-
formed through a small intercostal incision over 
the left ventricular apex with the use of a dedicat-
ed delivery catheter and the same SAPIEN valve.
Heparin was administered during the proce-
dure, and dual antiplatelet therapy (aspirin and 
clopidogrel) was recommended for 6 months af-
terward. The outpatient regimen was frequently 
modified by the treating physicians because of 
increased bleeding risks.
Study Design and Oversight
The study design and data-management practices 
have been described previously.16,17 A total of 699 
patients from 25 sites were randomly assigned to 
TAVR or surgical replacement. Patients assigned 
to TAVR were treated by either the transfemoral or 
transapical approach on the basis of whether pe-
ripheral arteries could accommodate the large 
sheaths required (22 French for the 23-mm valve 
and 24 French for the 26-mm valve). Patients who 
were randomly assigned to surgical replacement 
were stratified according to whether a transfemo-
ral or transapical approach would have been used.
The study was designed and monitored by the 
sponsor, Edwards Lifesciences, and the executive 
committee, which included four interventional 
cardiologists and four cardiac surgeons. The spon-
sor funded the study and participated in the se-
lection and management of the sites, the collec-
tion of the data, and data monitoring. The first 
author and members of the executive committee 
had unrestricted access to the data after the data-
base had been locked and prepared all drafts of 
the manuscript; they attest to the completeness 
and accuracy of the reported data and to the ad-
herence of the study to the protocol (available with 
the full text of this article at NEJM.org). The trial 
was approved by the institutional review board 
at each site. Written informed consent was ob-
tained from all patients.
Study End Points
The prespecified primary end point of the PART-
NER trial was all-cause mortality at 1 year for the 
pooled cohort. Prespecified secondary end points 
included cardiovascular mortality, stroke, repeat 
hospitalization, acute kidney injury, vascular com-
plications, bleeding events, and New York Heart 
Association (NYHA) functional class. All patients 
were followed for at least 2 years and had annual 
clinical visits and echocardiographic evaluations. 
Crossovers between the two treatment groups were 
not permitted. A clinical-events committee was 
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responsible for adjudicating all end points. Defi-
nitions of the end points are identical to those in 
the original trial and have been reported else-
where.16,17
Statistical Analysis
For data analyses, the intention-to-treat analysis 
started at the time of randomization, and the as-
treated analysis started at the time of induction 
of anesthesia in the procedure room. All clinical 
outcomes were primarily analyzed with the use 
of an intention-to-treat analysis, but the results 
of as-treated analyses are also presented for com-
parison. All echocardiographic analyses were per-
formed with the use of the as-treated data. Cat-
egorical variables were compared with the use of 
Fisher’s exact test. Continuous variables, presented 
as means ±SD, were compared with the use of 
Student’s t-test. Survival curves for time-to-event 
variables were constructed with the use of Kap-
lan–Meier estimates based on all available data 
and were compared with the use of the log-rank 
test. To study the effect of risk factors on mortal-
ity, Cox proportional-hazards regression was per-
formed. For the multivariable analyses, multiple 
imputations were used to accommodate missing 
baseline variables. The multivariable models in-
cluded covariates with a P value of less than 0.20 
in univariate analyses. An additional time-depen-
dent covariate analysis was performed to test the 
association of complications during TAVR or sur-
gical replacement with subsequent mortality. All 
statistical analyses were performed with the use 
of SAS software, version 9.2.
R esult s
Patients
In the randomized TAVR group, 244 patients had 
acceptable vascular access and were treated by 
means of the transfemoral approach, and the re-
maining 104 patients were treated by means of 
the transapical approach. Surgical replacement 
was performed in 351 patients. Figure 1 in the 
Supplementary Appendix, available at NEJM.org, 
shows the study-group assignments and follow-
up. All patients were followed for at least 2 years 
(median, 727 days; maximum, 1490 days). The 
overall study population was elderly (mean age, 
84.1±6.6 years), had severe cardiac symptoms 
(94.1% had NYHA class III or IV status), and had 
frequent coexisting conditions (75.5% had a his-
tory of coronary artery disease, 43.0% had a his-
tory of coronary-artery bypass surgery, 42.4% had 
peripheral vascular disease, 43.3% had pulmo-
nary disease, and 41.3% had diabetes). The TAVR 
and surgery groups were generally well matched 
with regard to baseline characteristics (Table 1 
in the Supplementary Appendix), except for a 
slightly higher incidence of renal dysfunction in 
the TAVR group (creatinine level >2 mg per deci-
liter [177 µmol per liter]: 10.8%, as compared 
with 6.4% in the surgery group; P = 0.04). The 
mean Society of Thoracic Surgeons predicted risk 
of death at 30 days was 11.8±3.4%.
Of the 699 study patients, 42 did not receive 
the assigned therapy: 4 in the TAVR group and 38 
in the surgery group.17 The main reasons for non-
treatment were withdrawal from the study and 
the patient’s decision not to undergo surgery (28 
patients).
Mortality and Stroke
Outcomes at 30 days and 1 year have been de-
scribed previously.17 For the duration of the trial, 
there were no significant differences in survival 
between the TAVR and surgery groups in either 
the intention-to-treat analysis (hazard ratio with 
TAVR, 0.90; 95% confidence interval [CI], 0.71 to 
1.15; P = 0.41) or the as-treated analysis (hazard 
ratio, 0.98; 95% CI, 0.76 to 1.25; P = 0.85) (Fig. 1). 
Between 1 and 2 years, there were 32 additional 
deaths in the TAVR group and 25 in the surgery 
group. At 2 years, there were no significant dif-
ferences in mortality from any cause between the 
TAVR group (33.9%; 95% CI, 28.9 to 39.0) and 
the surgery group (35.0%; 95% CI, 29.8 to 40.2; 
P = 0.78) (Table 1). Cardiovascular mortality at 
2 years was also similar in the TAVR and surgery 
groups (21.4% [95% CI, 16.8 to 26.0] and 20.5% 
[95% CI, 15.8 to 25.3], respectively; P = 0.80). Sim-
ilarly, in the as-treated analysis, the TAVR and sur-
gery groups did not differ significantly with re-
spect to all-cause mortality (33.9% and 32.7%, 
respectively; P = 0.75) or cardiovascular mortality 
(20.8% and 18.5%, respectively; P = 0.50) (Table 2 
in the Supplementary Appendix).
Between 1 and 2 years, eight strokes occurred 
(four in the TAVR group and four in the surgery 
group) and three transient ischemic attacks (two 
in the TAVR group and one in the surgery group). 
The frequency of all neurologic events (strokes and 
transient ischemic attacks) at 2 years was higher 
with TAVR than with surgical replacement (11.2% 
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vs. 6.5%, P = 0.05). However, there was no signifi-
cant difference in the number of overall strokes 
between the TAVR and surgery groups (hazard 
ratio, 1.22; 95% CI, 0.67 to 2.23; P = 0.52) (Fig. 1). 
After the early increased hazard of stroke in the 
first 30 days associated with TAVR (4.6% with 
TAVR vs. 2.4% with surgical replacement, P = 0.12), 
there were 8 additional strokes in the TAVR group 
and 12 in the surgery group, such that the total 
number of strokes over the follow-up period (36 
months) was 24 in the TAVR group and 20 in the 
surgery group. The composite of the rate of death 
from any cause or stroke did not differ signifi-
cantly between the two treatment groups (hazard 
ratio, 0.93; 95% CI, 0.73 to 1.18; P = 0.55) (Fig. 1); 
at 2 years, the rate was 37.1% in the TAVR group 
and 36.4% in the surgery group (P = 0.85).
Other Clinical Outcomes
Other clinical events are summarized in Table 1. 
Major vascular complications and major bleeding 
events were frequent procedure-related complica-
tions in the TAVR and surgery groups, respec-
tively, but after 1 year, these events were uncom-
mon and did not differ significantly between the 
groups. No patients were treated with balloon aor-
tic valvuloplasty or repeat TAVR between 1 and 
2 years. Endocarditis was rare and occurred at a 
similar rate in the two groups (1.5% in the TAVR 
group and 1.0% in the surgery group, P = 0.61). 
No patients in either group had structural valve 
deterioration requiring surgical replacement dur-
ing follow-up.
At 2 years, there was no significant difference 
in the rate of repeat hospitalization between the 
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Figure 1. Time-to-Event Curves for the Primary and Other Selected End Points.
Events were calculated with the use of Kaplan–Meier methods and compared with the use of a log­rank test. TAVR denotes transcatheter 
aortic­valve replacement.
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TAVR and surgery groups (24.7% and 21.7%, re-
spectively; P = 0.41). Among survivors at 2 years, 
the mean NYHA class was similar in the TAVR 
and surgery groups (1.72 and 1.70, P = 0.87), and 
the majority of patients in both groups had NYHA 
class I or II status (83.9% in the TAVR group and 
85.2% in the surgery group). Clinical outcomes in 
the subgroups of patients in whom a transfemo-
ral or transapical approach was used are shown 
in Tables 3 through 6 in the Supplementary Ap-
pendix.
Predictors of Mortality
Predictors of mortality for the overall trial cohort 
as well as for each of the randomized groups are 
presented in Table 2. Treatment assignment was 
not a significant predictor of the risk of death.
The time-dependent effect of treatment com-
plications on subsequent mortality was also eval-
uated. Strokes greatly increased the hazard of 
death in both groups (TAVR: hazard ratio, 2.47; 
95% CI, 1.42 to 4.30; P<0.001; surgery: hazard 
ratio, 5.20; 95% CI, 3.07 to 8.80; P<0.001). Major 
Table 1. Clinical Outcomes at 1 Year and 2 Years with TAVR or Surgery (Intention-to-Treat Population).*
Outcome 1 Year 2 Years
Surgery 
(N = 351)
TAVR 
(N = 348) P Value†
Surgery 
(N = 351)
TAVR 
(N = 348) P Value†
no. of patients (%) no. of patients (%)
Death
From any cause 89 (26.8) 84 (24.3) 0.45 114 (35.0) 116 (33.9) 0.78
From cardiovascular causes 40 (13.0) 47 (14.3) 0.63 59 (20.5) 67 (21.4) 0.80
Repeat hospitalization‡ 51 (17.7) 59 (18.6) 0.78 60 (21.7) 74 (24.7) 0.41
Death from any cause or repeat 
 hospitalization‡
125 (37.7) 121 (34.9) 0.45 152 (46.5) 159 (46.6) 0.99
Stroke or TIA§
All 13 (4.3) 28 (8.7) 0.03 18 (6.5) 34 (11.2) 0.05
Stroke 10 (3.2) 20 (6.0) 0.08 14 (4.9) 24 (7.7) 0.17
TIA 4 (1.5) 8 (2.6) 0.32 5 (2.0) 10 (3.6) 0.26
Death from any cause or stroke 95 (28.6) 95 (27.4) 0.74 119 (36.4) 127 (37.1) 0.85
Myocardial infarction 2 (0.6) 0 0.16 4 (1.5) 0 0.05
Major vascular complication¶ 13 (3.8) 39 (11.3) <0.001 13 (3.8) 40 (11.6) <0.001
Major bleeding‖ 88 (26.7) 52 (15.7) <0.001 95 (29.5) 60 (19.0) 0.002
Endocarditis 3 (1.0) 2 (0.6) 0.63 3 (1.0) 4 (1.5) 0.61
Renal failure** 20 (6.5) 18 (5.4) 0.57 21 (6.9) 20 (6.2) 0.75
New pacemaker 16 (5.0) 21 (6.4) 0.44 19 (6.4) 23 (7.2) 0.69
SVD requiring surgical replacement 0 0 0 0
* All percentages are Kaplan–Meier estimates at the specific time point and thus do not equal the number of patients 
divided by the total number in the study group. SVD denotes structural valve deterioration, TAVR transcatheter aortic­
valve replacement, and TIA transient ischemic  attack.
† P values are for between­group comparisons of the frequency of the event at each time point.
‡ Repeat hospitalizations were included in the analysis if they were for symptoms of heart failure, angina, or syncope 
due to aortic­valve disease that required aortic­valve intervention or intensified medical management.
§ Stroke was defined as a neurologic deficit lasting more than 24 hours or lasting less than 24 hours with a brain­imag­
ing study showing infarction.
¶ Major vascular complications were defined as thoracic aortic dissection; access­site or access­related vascular injury 
leading to death, the need for substantial blood transfusion (>3 units), or percutaneous or surgical intervention; and 
distal embolization (noncerebral) from a vascular source requiring surgery or amputation or resulting in irreversible 
end­organ damage.
‖ Major bleeding was defined as any episode of major internal or external bleeding that caused death, hospitalization, 
or permanent injury or that necessitated the transfusion of at least 3 units of packed red cells or a pericardiocentesis 
procedure.
** Renal failure was defined as any condition requiring the initiation of any dialysis.
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bleeding also increased the hazard of death in 
both groups (TAVR: hazard ratio, 2.11; 95% CI, 
1.41 to 3.17; P<0.001; surgery: hazard ratio, 2.94; 
95% CI, 2.08 to 4.15; P<0.001). Major vascular 
complications affected survival only in the TAVR 
group (hazard ratio, 1.71; 95% CI, 1.07 to 2.73; 
P = 0.02).
Echocardiographic Findings
The early hemodynamic improvements that were 
seen with both surgical replacement and TAVR 
were maintained at 2 years, with no significant 
changes in valve areas or mean gradients (Fig. 2). 
Moderate or severe paravalvular aortic regurgita-
tion was more common after TAVR than after 
surgical replacement at both 1 and 2 years (7.0% 
vs. 1.9% at 1 year, and 6.9% vs. 0.9% at 2 years; 
P<0.001 for both comparisons). Among the 143 
patients who underwent echocardiographic eval-
uation 2 years after TAVR, paravalvular aortic re-
gurgitation remained unchanged in 46.2% of pa-
tients, was improved in 31.5%, and was worse in 
22.4% (Table 7 in the Supplementary Appendix). 
The presence of paravalvular or total aortic re-
gurgitation (mild, moderate, or severe vs. none or 
trace) after TAVR was associated with increased 
late mortality (hazard ratio, 2.11; 95% CI, 1.43 to 
3.10; P<0.001) (Fig. 3). The effect of aortic regur-
gitation on mortality was proportional to the se-
verity of the regurgitation (Fig. 3), but even mild 
aortic regurgitation was associated with an in-
creased rate of late deaths.
Discussion
The salient findings from this 2-year analysis of 
the randomized PARTNER trial are as follows: 
mortality after TAVR remained similar to that 
Table 2. Multivariable Predictors of Mortality.*
Variable
Hazard Ratio  
(95% CI) P Value
Overall
TAVR group 0.89 (0.70–1.13) 0.34
Body­mass index† 0.96 (0.94–0.98) <0.001
Liver disease‡ 2.24 (1.30–4.00) 0.006
Mean gradient per increase of 10 mm Hg 0.89 (0.81–0.98) 0.02
STS risk score§ 1.04 (1.01–1.08) 0.02
Moderate or severe mitral regurgitation at baseline 1.36 (1.02–1.82) 0.04
TAVR
Body­mass index† 0.93 (0.90–0.97) <0.001
Mean gradient per increase of 10 mm Hg 0.82 (0.72–0.94) 0.003
Creatinine level at baseline¶ 1.06 (1.00–1.13) 0.04
Prior vascular surgery or stent 1.85 (1.01–3.39) 0.05
Surgery
CABG 0.57 (0.40–0.82) 0.002
STS risk score§ 1.07 (1.02–1.12) 0.004
Liver disease‡ 2.59 (1.16–5.43) 0.02
Moderate or severe mitral regurgitation at baseline 1.77 (1.17–2.68) 0.006
* Unless otherwise indicated, the hazard ratio reflects the presence or absence of the variable. CABG denotes coronary­
artery bypass grafting.
† For body­mass index (the weight in kilograms divided by the square of the height in meters), the hazard ratio reflects 
an increase of 1.
‡ Liver disease indicates a history of any liver condition.
§ The Society of Thoracic Surgeons (STS) risk score predicts the 30­day risk of death (on a scale of 0% to 100%, with 
higher scores indicating higher predicted risk). The hazard ratio reflects an increase of 1%.
¶ For creatinine level at baseline, the hazard ratio reflects an increase of 1 mg per deciliter.
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after surgical replacement, stroke frequency was 
similar in the surgery and TAVR groups after 
30 days, periprocedural complications (strokes, 
major bleeding, and major vascular events) affect-
ed mortality after TAVR or surgical replacement; 
aortic regurgitation (even mild) after TAVR was 
associated with increased long-term mortality, and 
valve performance in the TAVR group was main-
tained during follow-up and was similar to that 
in the surgery group.
Early (30-day) mortality after TAVR has de-
creased to approximately 5% in several recent 
studies, probably because of a combination of im-
provements in patient selection, procedural tech-
niques, and device technologies.12,14,16-18 How-
ever, 1- and 2-year mortality rates have remained 
above 20% and 30%, respectively,11,15,19,20 rais-
ing a concern that TAVR may be associated with 
important late complications. The results from 
the PARTNER trial reveal similarly high mortal-
ity at 2 years with TAVR and with surgical re-
placement, indicating that coexisting conditions 
play a role in late mortality. The multivariable 
analysis from the combined TAVR and surgery 
groups affirms the importance of coexisting con-
ditions, because the STS risk score was a signifi-
cant predictor of mortality at 2 years. Although 
the STS score was designed to predict 30-day mor-
tality after surgical replacement,21 many of the 
baseline characteristics of the patients are also 
likely contributors to late mortality.
The 30-day and 1-year PARTNER results raised 
concern that TAVR was responsible for increased 
early and, possibly, late strokes.16,17 The differ-
ences in stroke frequencies appeared in the first 
few days or weeks after TAVR, presumably owing 
to increased liberation of atherothrombotic debris 
(from the valve or aorta), causing embolic ische-
mic strokes. After this initial period, there is no 
evidence of higher stroke rates in either group, 
suggesting that the constant hazard of late strokes 
in these elderly high-risk patients is unrelated to 
the mode of valve-replacement therapy. The pre-
ferred anticoagulation regimen (early and late) for 
patients after TAVR has not been determined.22 
Early experiences with new cerebral filters23 sug-
gest the frequent appearance of captured ath-
erothrombotic material after TAVR, but careful 
clinical studies with these new devices are just 
beginning.
The current study shows stable gradients and 
unchanged valve areas with the SAPIEN valve at 
2 years. Nevertheless, structural valve deterioration 
is well known with surgical bioprostheses, and 
definitive assessments of valve durability will re-
quire much longer follow-up.24-26
A design limitation of transcatheter aortic 
valves has been paravalvular regurgitation, which 
results from incomplete circumferential apposi-
tion of the prosthesis with the annulus. Several 
reports have indicated a relation between para-
valvular regurgitation and mortality, but the cer-
tainty of these findings has been limited by the 
lack of standardization of methods to assess aor-
tic regurgitation.11,12,27,28 In our study, semiquan-
titative measures of aortic-regurgitation severity 
were evaluated in an echocardiography core labo-
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Figure 2. Echocardiographic Findings.
Panel A shows the aortic­valve area in the as­treated population; between­
group differences were significant at 30 days through 1 year. Panel B shows 
the mean gradient in the as­treated population; between­group differences 
were significant at 30 days and 1 year. Error bars represent 1 SD in both 
panels.
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ratory; these assessments indicated a low fre-
quency of moderate or severe paravalvular aortic 
regurgitation (approximately 10%). Paravalvular 
aortic regurgitation remained stable without sig-
nificant worsening during follow-up. Neverthe-
less, even mild paravalvular (or total) aortic re-
gurgitation (occurring in approximately 40% of 
patients) was associated with increased late mor-
tality (Fig. 3). Conversely, the absence of paraval-
vular aortic regurgitation or only trace regurgi-
tation was associated with lower mortality in the 
TAVR group.
These findings provide an important target 
for improving outcomes after TAVR in the future. 
The factors that underlie paravalvular aortic re-
gurgitation include the ratio of the transcatheter-
valve size to the size of the annulus, the position 
of the prosthetic valve, and the pattern of calci-
fication in the native valve.29-32 In the PARTNER 
trial, the valve cover index,32 defined as 100 × 
[(valve prosthesis diameter − annulus diameter) ÷ 
valve prosthesis diameter], was lower in patients 
with paravalvular aortic regurgitation, implicat-
ing systematic valve undersizing as an important 
causative factor. Recently, the routine use of three-
dimensional imaging techniques has improved 
annulus sizing, resulting in better selection of 
properly sized valves.33-37 In addition, the selec-
tive use of post-TAVR dilation of the transcatheter 
valve with slightly larger balloons may reduce im-
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Figure 3. Relation of Aortic Regurgitation to All-Cause Mortality in the TAVR As-Treated Population.
Events were calculated with the use of Kaplan–Meier methods.
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mediate paravalvular aortic regurgitation during 
TAVR, but the risks of aortic rupture, increased 
central aortic regurgitation, and increased embolic 
events must be considered. Future generations of 
TAVR devices with improved subannular fixa-
tion designs or external space-filling materials 
may also reduce incomplete apposition.
Several study limitations should be acknowl-
edged. First, patients frequently declined surgery 
after random assignment to surgical replacement, 
resulting in a higher proportion of patients in the 
surgery group who did not receive the assigned 
treatment. Nonetheless, there were no significant 
differences in clinical outcomes between the in-
tention-to-treat cohort and the as-treated cohort. 
Second, stroke assessments were limited, since 
neurologic assessments were not mandated, modi-
fied Rankin scores were not used to determine 
clinical disability, and documentation of atrial fi-
brillation episodes and anticoagulation regimens 
was not complete. Third, the small number of pa-
tients in whom the transapical approach was 
used and the differences in baseline character-
istics make a comparison of the transfemoral 
and transapical subgroups unreliable. Finally, 
this study represented the initial experience with 
TAVR at most of the sites, with the use of a 
first-generation device. Multiple reports suggest 
that subsequent device generations and increased 
operator experience with TAVR may improve out-
comes.18,38-40
In conclusion, this 2-year follow-up of patients 
in the PARTNER trial supports the use of TAVR 
as an alternative to surgery in selected high-risk 
patients with aortic stenosis. The two treatments 
were similar with respect to mortality, reduction 
in cardiac symptoms, and improved valve hemo-
dynamics. The early increase in the risk of stroke 
with TAVR was attenuated over time. A new, im-
portant observation was the association of para-
valvular regurgitation after TAVR with late mor-
tality. Work now should be directed toward 
reducing paravalvular aortic regurgitation with 
improved device designs, techniques for more pre-
cise valve sizing and positioning, and judicious 
use of post-TAVR dilation.
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